Skip to main content
SpringerLink
Log in

Plerixafor

In Patients with Non-Hodgkin’s Lymphoma or Multiple Myeloma

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ The bicyclam plerixafor mobilizes haematopoietic stem cells (HSCs) from the bone marrow into the peripheral blood circulation and augments the effects of granulocyte colony-stimulating factor (G-CSF).

  • ▴ More patients requiring autologous HSC transplantation for non-Hodgkin’s lymphoma or multiple myeloma in first or second remission achieved goal increases in mobilized CD34+ cells after subcutaneous plerixafor 240 μg/kg/day for up to four apheresis days in conjunction with a G-CSF treatment regimen than after placebo plus G-CSF.

  • ▴ Sufficient CD34+ cells for transplantation were collected earlier for recipients of plerixafor plus G-CSF (often after one apheresis) than for patients receiving placebo plus G-CSF.

  • ▴ Time to engraftment and durability of grafts after 12 months were similar for both plerixafor plus G-CSF and placebo plus G-CSF.

  • ▴ In a compassionate-use trial in patients with non-Hodgkin’s lymphoma, multiple myeloma or Hodgkin’s disease in whom prior mobilization attempts were unable to stimulate sufficient cells, therapy with the plerixafor/G-CSF combination regimen was successful in ≥60% of patients.

  • ▴ Plerixafor appears to be generally well tolerated; most adverse effects in clinical trials were mild and transient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Montgomery M, Cottler-Fox M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. Clin Adv Hematol Oncol 2007 Feb; 5(2): 127–36

    PubMed  Google Scholar 

  2. Flomenberg N, DiPersio J, Calandra G. Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells. Acta Haematol 2005; 114(4): 198–205

    Article  PubMed  CAS  Google Scholar 

  3. Klocke R, Kuhlmann MT, Scobioala S, et al. Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications. Curr Med Chem 2008; 15(10): 968–77

    Article  PubMed  CAS  Google Scholar 

  4. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008 Sep; 14(9): 1045–56

    Article  PubMed  CAS  Google Scholar 

  5. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008 Aug 15; 112(4): 990–8

    Article  PubMed  CAS  Google Scholar 

  6. Rosenkilde MM, Gerlach L-O, Jakobsen JS, et al. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 2004 Jan 23; 279(4): 3033–41

    Article  PubMed  CAS  Google Scholar 

  7. Gerlach LO, Skerlj RT, Bridger GJ, et al. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 2001 Apr 27; 276(17): 14153–60

    PubMed  CAS  Google Scholar 

  8. Hatse S, Princen K, Bridger G, et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR 4. FEBS Lett 2002 Sep 11; 527(1–3): 255–62

    Article  PubMed  CAS  Google Scholar 

  9. Dar A, Kalinkovich A, Netzer N, et al. AMD3100 signals via the nervous system, inducing release to the circulation of bone marrow SDF-1, which is crucial for progenitor cell mobilization [abstract no. 1315]. Blood 2006 Nov; 108 (11 Pt 1): 385a

    Google Scholar 

  10. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005 Apr 18; 201(8): 1307–18

    Article  PubMed  CAS  Google Scholar 

  11. Martin C, Bridger GJ, Rankin SM. Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro. Br J Haematol 2006 Aug; 134(3): 326–9

    Article  PubMed  CAS  Google Scholar 

  12. Hess DA, Bonde J, Craft TC, et al. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant 2007 Apr; 13(4): 398–411

    Article  PubMed  CAS  Google Scholar 

  13. Burroughs L, Mielcarek M, Little M-T, et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005 Dec 1; 106(12): 4002–8

    Article  PubMed  CAS  Google Scholar 

  14. Marquez-Curtis LA, Montano J, Quinn D, et al. In vitro chemotactic index and response to CXCR4 antagonist AMD3100 correlate with CD34+ cell yield from leuka-pheresis products: implications for poor mobilizers [abstract no. 727]. Blood 2006 Nov; 108 (11 Pt 1): 218a

    Article  Google Scholar 

  15. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocytecolony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion (Paris) 2005 Mar; 45(3): 295–300

    CAS  Google Scholar 

  16. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol 2004 Mar 15; 22(6): 1095–102

    Article  PubMed  CAS  Google Scholar 

  17. Gazitt Y, Freytes CO, Akay C, et al. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granuloycyte-colony-stimulating factor in non-Hodgkin’s lymphoma patients. Stem Cells Dev 2007; 16: 657–66

    Article  PubMed  CAS  Google Scholar 

  18. Donahue RE, Jin P, Bonifacino AC, et al. AMD3100 and granulocyte colony stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression [abstract no. 1385]. Online program and abstracts from the 50th ASH Annual Meeting and Exposition; 2008 Dec 6–9; San Francisco (CA) [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper13068.html[Accessed 2009 Feb 4]

  19. Fruehauf S, Seeger T, Maier P, et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006; 34(8): 1052–9

    Article  PubMed  CAS  Google Scholar 

  20. Rettig MP, Shannon WD, Ritchey J, et al. Characterization of human CD34+ hematopoietic stem cells following administration of G-CSF or plerixafor [abstract no. 3476]. Online program and abstracts from the 50th ASH Annual Meeting and Exposition; 2008 Dec 6–9; San Francisco (CA) [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper14936.html[Accessed 2009 Jan 29]

  21. Fruehauf S, Seeger T, Dillmann F, et al. The CXCR4 antagonist AMD3100 mobilizes a more primitive subset of CD34+ cells than G-CSF [abstract no. 443]. Onkologie 2005 Oct; 28 (Suppl. 3): 145

    Google Scholar 

  22. Devine S, Gazitt Y, Calandra G. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin’s lymphoma or multiple myeloma [letter]. J Clin Oncol 2005 Jun 1; 23(16): 3872–3

    Article  Google Scholar 

  23. Fruehauf S, Seeger T, Topaly J, et al. The CXCR4-antagonist AMD3100 augments the number of mobilized peripheral blood progenitor cells (PBPC) when added to a G-CSF standard mobilization regime and AMD3100-mobilized PBPC result in rapid hematopoietic reconstitution after autologous transplantation [abstract no. 574]. Onkologie 2005 Oct; 28 (Suppl. 3): 187

    Google Scholar 

  24. Rettig MP, Ramirez P, Shannon WD, et al. Kinetics of stem cell and lymphoid subset mobilization in response to intravenous (IV) AMD3100 in mouse and man [abstract no. 1203]. Blood 2007 Nov 16; 110 (11 Pt 1): 365a

    Google Scholar 

  25. Hendrix CW, Flexner C, MacFarland RT, et al. Pharma-cokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000 Jun; 44(6): 1667–73

    Article  PubMed  CAS  Google Scholar 

  26. Hübel K, Liles WC, Broxmeyer HE, et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004 Apr 1; 1(3): 165–72

    Article  PubMed  Google Scholar 

  27. Lack NA, Green B, Dale DC, et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD 3100. Clin Pharmacol Ther 2005 May; 77(5): 427–36

    Article  PubMed  CAS  Google Scholar 

  28. MacFarland R, Ewesuedo RB, Badel K, et al. Pharmaco-kinetics of plerixafor (AMD3100) in volunteers with renal impairment [abstract no. 2878]. Blood 16 Nov 2007; 110 (11 Pt 1): 847A

    Article  Google Scholar 

  29. McFarland R, Scarborough R, Becker S, et al. Pharmaco-kinetics of AMD3100 in volunteers with renal impairment [abstract no. P681]. Bone Marrow Transplant 2007 Apr; 39 (Suppl. 1): S155

    Google Scholar 

  30. McFarland R, Stewart D, Cashen A, et al. Pharmacokinetics of AMD3100 in patients with haematologic malignancies [abstract no. P619]. Bone Marrow Transplant 2007 Apr; 39 (Suppl. 1): S132

    Google Scholar 

  31. Douglas S, Smith C, McFarland R, et al. AMD3100 with G-CSF for autologous peripheral blood progenitor cell (PBPC) mobilization in non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM): mobilization, engraftment, and pharmacokinetics (PK) [abstract no. 3383]. Blood 2006 Nov; 108 (11 Pt 1): 966a

    Google Scholar 

  32. Cashen A, Lopez S, Gao F, et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1253–61

    Article  PubMed  CAS  Google Scholar 

  33. Stewart DA, Smith C, MacFarland R, et al. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 39–46

    Article  PubMed  CAS  Google Scholar 

  34. Genzyme Corporation. Mozobil® (plerixafor injection): prescribing information [online]. Available from URL: http://www.genzyme.com/corp/investors/Mobozil_PI.pdf[Accessed 2009 Feb 4]

  35. DiPersio JF, Micallef I, Stiff PJ, et al. A phase III, multi-center, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs. placebo+G-CSF in non-Hodgkin’s lymphoma patients for autologous hematopoietic stem cell (aHSC) transplantation [abstract no. 601]. Blood 2007 Nov 16; 110 (11 Pt 1): 185a

    Google Scholar 

  36. DiPersio JF, Micallef INM, Stiff PJ, et al. 12 months report from the phase 3 study of plerixafor+G-CSF vs. placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL [abstract no. 1136]. Online Program and Abstracts from the 50th ASH Annual Meeting and Exposition; 2008 Dec 6–9; San Francisco (CA) [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper3053.html[Accessed 2009 Feb 4]

  37. DiPersio J, Stadtmauer EA, Nademanee AP, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [abstract no. 445]. Blood 2007 Nov 16; 110 (11 Pt 1): 137–8a

    Google Scholar 

  38. DiPersio JF, Stadtmauer EA, Nademanee AP, et al. 12 months report from a phase 3 study of plerixafor+G-CSF vs. placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma [abstract no. 3312]. Online Program and Abstracts from the 50th ASH Annual Meeting and Exposition; 2008 Dec 6–9; San Francisco (CA) [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper3236.htm[Accessed 2009 Feb 4]

  39. Dugan MJ, Akard LP, Thompson JM, et al. Treatment with AMD3100 in multiple myeloma or non-Hodgkin’s lymphoma patients to increase the number of peripheral blood stem cells when given with a mobilizing regimen of chemotherapy and G-CSF [abstract no. 2860]. Blood 2004 Nov 16; 104 (11 Pt 1):782a

    Google Scholar 

  40. Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249–56

    Article  PubMed  CAS  Google Scholar 

  41. Flomenberg N, Comenzo R, Badel K, et al. Single agent AMD3100 mobilization of peripheral blood progenitor cells for autologous transplantation in patients with multiple myeloma (MM) [abstract no. 3381]. Blood 2006 Nov; 108 (11 Pt 1):965a

    Article  Google Scholar 

  42. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005 Sep 1; 106(5): 1867–74

    Article  PubMed  CAS  Google Scholar 

  43. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41(4): 331–8

    Article  PubMed  CAS  Google Scholar 

  44. Stiff PJ, Micallef INM, Nademanee AP, et al. Transplanted CD34+ cell dose is associated with long-term platelet count following autologous hematopoietic stem cell transplant in patients with non-Hodgkin’s lymphoma and multiple myeloma [abstract no. 2175]. Online program and abstracts of the 50th ASH Annual Meeting and Exposition; 2008 Dec 6–9; San Francisco (CA) [online]. Available from URL: http://ash.confex.com/ash/2008/webprogram/Paper3358.html[Accessed 2009 Jan 29]

  45. Micallef I, Stiff PJ, DiPersio JF, et al. Successful stem cell mobilization rescue by AMD3100 (Plerixafor)+G-CSF for patients who failed primary mobilization: results from the phase III (3101-NHL) study [abstract no. 602]. Blood 2007 Nov 16; 110 (11 Pt 1): 185–6a

    Google Scholar 

  46. Dale DC, Rodger E, Christensen JJ, et al. Optimizing the use of AMD3100, a CXCR-4 antagonist, for mobilization of hematopoietic progenitor cells: studies in healthy volunteers [abstract no. 123]. Blood 2003 Nov 16; 102 (11 Pt 1): 38a

    Google Scholar 

  47. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003 Oct 15; 102(8): 2728–30

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements and Disclosures

The manuscript was revewed by: M. Cottler-Fox, Cell Therapy and Transfusion Medicine, Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA; L. Lekakis, Department of Hematology, Medical Oncology and Blood and Marrow Transplantation, University of Kentucky, Lexington, Kentucky, USA; L. Porrata, Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

The preparation of this review was not supported by any external funding. During the review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from any comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Antona J. Wagstaff

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Antona J. Wagstaff

Authors
  1. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antona J. Wagstaff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagstaff, A.J. Plerixafor. Drugs 69, 319–326 (2009). https://doi.org/10.2165/00003495-200969030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200969030-00007

Keywords

Search

Navigation